Analysis of HER2 gene status in breast cancer with HER2 protein overexpression

Chinese Journal of Pathology

Volumn 35, Issue 10, 2006, Pages 584-588

  Zeng, Xuan ^a   Liang, Zhi Yong ^a   Wu, Sha Fei ^a   Zhou, Wei Xun ^a   Gao, Jie ^a   Liu, Tong Hua ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

Breast neoplasms; Chromosomes, human, pair 17; Genes, erbB 2; Immunohistochemistry; In situ hybridization, Fluorescence

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORMALDEHYDE; PARAFFIN;

ARTICLE; BREAST CANCER; CANCER TISSUE; CHROMOSOME 17; CHROMOSOME ANALYSIS; CONTROLLED STUDY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MIDDLE AGED; RECEPTOR, ERBB-2; YOUNG ADULT;

EID: 33845193694     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA, 2004, 291:1972-1977.
2. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res,2005, 11:6598-6607.
3. Dolan M, Snover D. Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol,2005, 123:766-770.
4. Lan C, Liu JM, Liu TW, erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2 + in immunohistochemical analysis. Am J Clin Pathol,2005, 124:97-102.
5. Merola R, Mottolese M, Orlandi G, et al. Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2 + in immunohistochemical analysis. Eur J Cancer,2006, 42:1501-1506.
6. Salido M, Tusquets I, Corominas JM, et al. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry. Breast Cancer Res, 2005, 7: R267-R273.
7. Watters AD, Going JJ, Cooke TG, et al. Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma. Breast cancer Res Treat,2003, 77:109-114.
8. Wang S, Hossein Saboorian H, Frenkel EP, et al. Aneusomy 17 in breast cancer: its role in HER-2/neu protein expression and implication for clinical assessment of HER-2/neu status. Mod Pathol, 2002,15:137-145.
9. Schmidt M, Lewark B, Kohlschmidt N, et al. Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res, 2005, 7:R256-R266.
10. Chorn N. Accurate identification of HER2-positive patients is essential for superior outcomes with trastuzumab therapy. Oncol Nurs Forum, 2006,33:265-272.
11. Jacob TW, Gown AM, Yaziji H, et al. HER-2/neu protein expression in breast cancer evaluated by immunohistochemistry. A study of interlaboratory agreement. Am J Clin Pathol, 2000, 113:251-258.
12. Hammock L, Lewis M, Phillips C, et al. Strong HER-2/neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization. Hum Pathol,2003,34:1043- 1047.
13. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer, 2004,5:63-69.
14. Risio M, Casorzo L, Redana S, et al. HER2 gene-amplified breast cancers with monosomy of chromosome 17 are poorly responsive to trastuzumab-based treatment. Oncol Rep, 2005,13:305-309.